Between the 2 vaccines now available for protection against human papilloma virus (HPV), the quadrivalent vaccine may have an advantage over the bivalent vaccine with respect to costs and quality of life, but the bivalent vaccine may prevent more deaths from cervical cancer, according to new research.
Mark Jit, PhD, MPH, a mathematical modeler from the Health Protection Agency in London, United Kingdom, and colleagues published their findings online September 27 in the BMJ.
As described in the article, the HPV bivalent vaccine (Cervarix, GlaxoSmithKline) targets HPV types 16 and 18, which are estimated to cause more than 70% of cervical cancer cases worldwide. In contrast, in addition to HPV types 16 and 18, the quadrivalent vaccine (Gardasil, Merck) also targets HPV types 6 and 11, to which anogenital warts and recurrent respiratory papillomatoses are attributed.
In 2008, the UK government selected the bivalent vaccine for protection against HPV based on a previous analysis led by the same authors, indicating that the bivalent vaccine would have to be £15 to £23 cheaper per dose to be as cost-effective as the quadrivalent vaccine because of “the lack of protection against anogenital warts,” as understood at that time. Since then, however, new data have emerged. First, studies have indicated that both the bivalent and the quadrivalent vaccines may also be effective against certain oncogenic HPV types not included in the respective vaccines. In addition, the quadrivalent vaccine has shown protection against vulvar, vaginal, and anal cancer; and the bivalent vaccine has shown some protection against anal infection, which may ultimately translate into prevention of anal cancer.
A test that detects the two strains of human papillomavirus (HPV) that are most likely to raise the risk of invasive cervical cancer, when combined with the Pap test, may be more accurate for many women than the Pap test alone, a new study indicates. And, for those women who are HPV-positive, using the HPV test alone appears to be enough, said study author Philip Castle, a researcher at the American Society for Clinical Pathology Institute in Washington, D.C.
For the women who were HPV-positive, he said, “we didn’t need the Pap. We could have used the HPV alone and gotten the same results.”
The study was funded by Roche Molecular Systems, which makes an HPV test. The study is published online Aug. 22 in The Lancet Oncology.
The researchers looked at a DNA-based HPV test, made by Roche and approved in 2011 by the U.S. Food and Drug Administration.
Castle works as an unpaid consultant for the company. Other authors have received consulting fees from Roche or work as employees at the company.
Under cervical cancer screening guidelines issued by the American Cancer Society in 2002 and the American College of Obstetricians and Gynecologists in 2003, women aged 30 or older should have both a Pap test, also known as a Pap smear, as well as an HPV test, also called an HPV co-test. HPV is the most common sexually transmitted infection, and certain strains of the virus can cause cervical cancer.
Under current guidelines, if the results of both tests are normal, a woman can wait three years for her next Pap test, which looks for signs of cancer in cells from a woman’s cervix.
News
- U.S. cancer death rates continue to drop
- Lung cancer likely to overtake breast cancer as the main cause of cancer death among European women
- Squeezing Breasts Can Help Fight Breast Cancer
- Enzyme offers new therapeutic target for cancer drugs
- HPV Vaccine May Prevent Recurrence of Precancerous Conditions
- Survival Rate of Cancer Patients in Korea Ranked in the Top in the World
- Kids’ leukemia risk raised by dads who smoke
- Transplant recipients have a high risk of developing cancer
- CDC recommends that boys get vaccinated against HPV
- Cancer survivor population over 65 to increase over next decade
